LNP-RNA Therapeutics 2-Day Virtual Symposium Agenda

*All Times Listed in Eastern Daylight Time*

**All Information is Subject to Change**

Wednesday - April 6, 2022

8:50 AM - 9:00 AM - Welcome & Logistics

Juliana Haggerty, EngD

Head of Centre of Excellence - Lipid Nanoparticle


Dominik Witzigmann, PhD

Chief Executive Officer

NanoVation Therapeutics

9:00 AM - 9:30 AM - LNP-RNA History

The tangled history of mRNA-LNP vaccines

Elie Dolgin, PhD



9:30 AM - 10:45 AM - Session 1: RNA Therapeutics - Setting the Scene

Tailored LNP solutions for mRNA-based cancer immunotherapy

Stefaan De Koker

VP discovery

eTheRNA immunotherapies

Industrial perspective: translating mRNA LNPs from discovery to development

Marianna Yanez Arteta, PhD

Associate Director


Industrial perspective: translating mRNA LNPs from discovery to development

Alan Sabirsh, PhD

Principal Scientist


BREAK: 10:45 AM - 11:10 AM

11:10 AM - 12:25 PM - Session 2: Improved in vitro/in vivo Methods for Developing RNA Therapeutics

Lipid Nanoparticles for Extrahepatic Delivery of mRNA

Gaurav Sahay, PhD

Associate Professor

Oregon State University

Improved in vitro methods for safety assessment in development of RNA Therapeutics

Geir Klinkenberg, Dr.

Research Manager

SINTEF Industry

Delivering RNA to New Tissues by Testing Thousands of Nanoparticles in vivo

James Dahlman, PhD

Associate Professor

Georgia Institute of Technology

BREAK: 12:25 PM - 1:10 PM 

1:10 PM - 2:50 PM - Session 3: Genome Editing

Targeting metabolic liver diseases by in vivo base- and prime editing

Gerald Schwank, PhD


Universität Zürich



Multiplexed screening of LNPs in vivo enabled by nucleic acid barcoding

Cory Sago, PhD

Senior Director, Head of LNP Discovery

Beam Therapeutics

Writing DNA with RNA

Cecilia Cotta-Ramusino, PhD






Prime editing

Sabine Fuchs, PhD, MD, Pharmacist

Pediatrician and PI (Principal Investigator/Group Leader) in Metabolic Diseases

Associate Professor


BREAK: 2:50 PM - 3:10 PM 
3:10 PM - 4:00 PM - Session 4

Treatment of Rare Genetic Diseases using Gene Therapy


Pediatrician and Medical Geneticist

M.A.G.I.C. Clinic Ltd. in Calgary and Vancouver (Metabolics and Genetics in Canada)


Innovative therapies for Hemophilia: Way beyond substitution therapy

David Lillicrap, MD 


Queen's University




4:00 PM - 5:00 PM -  Panel Discussion on Unmet Clinical Needs/Rare Diseases

Panel Participant

Barbara D Insley, LL.B, CFA

Chair and Executive Director

Rare Trait Hope Society

5:00 PM - Closing Day 1


Thursday - April 7, 2022

8:50 AM -  Welcome and Logistics

Juliana Haggerty, EngD

Head of Centre of Excellence - Lipid Nanoparticle


Dominik Witzigmann, PhD

Chief Executive Officer

NanoVation Therapeutics

9:00 AM - 10:15 AM - Session 5: Future in RNA Design

Development of a 2nd generation SARs-CoV2 vaccine utilizing self-amplifying RNA and viral targets beyond Spike

Karin Jooss, PhD

Executive Vice President and Head of Research & Development

Gritstone bio

Leveraging the design of self-replicating RNA to enhance RNA therapeutics

Andrew Geall, PhD

Chief Development Officer

Replicate Bioscience

Programming mRNA for Cancer Immunotherapy

Tasuku Kitada, Ph.D.

Co-founder, Board Director, President, and Head of R&D

Strand Therapeutics

BREAK: 10:15 AM - 10:35 AM
10:35 AM - 11:50 AM - Session 6: Delivery Platform Technologies

Simultaneous quantification of multiple RNA cargoes co-loaded into nanoparticle-based delivery systems

Camilla Foged, PhD


University of Copenhagen


On the Structural Features of Lipid Nanoparticle Formulations of Nucleic Acids

Jayesh Kulkarni, PhD

Chief Scientific Officer

NanoVation Therapeutics

Next Generation lipids for RNA Delivery

Dan Peer, PhD

Professor and Director, Laboratory of Precision Nanomedicine

NeoVac & Tel Aviv University

BREAK: 11:50 AM - 12:35 PM
12:35 PM - 2:15 PM - Session 7: Manufacturing / New Technologies

Development of a Platform for LNP-RNA Manufacture - Challenges and Opportunities

Philip Probert, PhD             

Head of Technical


Digital Innovations in the Bio Pharma Industry

Adrian Abbotts, BSc Biotechnology

Business Development Manager Cell & Gene Therapies

Siemens Digital Industries

Next generation DNA templates for the production of mRNA

Amy Walker, PhD

Director of Discovery


Optimal Self-Assembly of Lipid Nanoparticles (LNP) in a Ring Micromixer

Mostafa Nakach, PhD

Section head of formulation & process development within Biologic drug product development & manufacturing


BREAK: 2:15 PM - 2:35 PM
2:35PM - 3:25 PM - Session 8: Cell therapies ex vivo/in vivo incl. Car-T

mRNA Lipid Nanoparticle Reprogramming of Immune Cell for the Treatment of Heart Disease

Haig Aghajanian, PhD

Adjunct Assistant Professor of Medicine

University of Pennsylvania

Ionizable Lipid Nanoparticles Induce potent Tfh responses and can serve as protein adjuvants

Mohamad-Gabriel Alameh, PhD

Director Engineered mRNA and Targeted Nanomedicine Core at UPenn

University of Pennsylvania

3:25 PM - 4:25 PM - Panel Discussion: Future of LNP-RNA Systems

Panel Discussion Lead

Sanya Puri, PhD



Panel Discussion: Next-Gen LNPs for Tissue/Cell-Specific Delivery

Priya Karmali, PhD            

Chief Technology Officer

Capstan Therapeutics  

Panel Discussion

Ruchi Shah, PhD           

Associate Director

Eli Lilly & Company

4:25 PM - Closing Day 2